2 files

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

posted on 16.03.2018, 12:07 by Peter Nash, Iain B. McInnes, Philip J. Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, • Steffen M. Jugl

Article full text

The full text of this article can be found here. https://link.springer.com/article/10.1007/s40744-018-0106-6

Provide enhanced content for this article

If you are an author of this publication and would like to provide additional enhanced content for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:

• Slide decks

• Videos and animations

• Audio abstracts

• Audio slides


Novartis Pharma AG